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Abstract
Background: Side effects of the immunosuppressive therapy after solid organ trans-
plantation	are	well	 known.	Recently,	 significant	benefits	were	 shown	 for	mTOR-Is	
with	respect	to	certain	viral	infections	in	comparison	with	CNIs.	However,	reported	
total	incidences	of	infections	under	mTOR-Is	vs	CNIs	are	usually	not	different.	This	
raises the question to additional differences between these immunosuppressants re-
garding development and incidence of infections.
Methods: The	current	literature	was	searched	for	prospective	randomized	controlled	
trials	in	renal	transplantation.	There	were	954	trials	screened	of	which	19	could	be	
included	 (9861	pts.).	 The	1-year	 incidence	of	 infections,	 patient	 and	graft	 survival	
were	assessed	in	meta-analyses.
Results: Meta-analysis	on	1-year	incidence	of	infections	showed	a	significant	benefit	
of	an	mTOR-I	based	therapy	when	combined	with	a	CNI	vs	CNI-based	therapy	alone	
(OR	0.76).	There	was	no	difference	between	mTOR-I	w/o	CNI	and	CNI	therapy	(OR	
0.97).	For	pneumonia,	a	significant	disadvantage	was	seen	only	for	mTOR-I	mono-
therapy	compared	to	CNI's	(OR	2.09).	The	incidence	of	CMV	infections	was	signifi-
cantly	reduced	under	mTOR-I	therapy	(combination	with	CNI:	OR	0.30;	mTOR	w/o	
CNI:	OR:	0.46).	There	was	no	significant	difference	between	mTOR-I	and	CNI	therapy	
with	respect	to	patient	survival	(mTOR-I	w/o	CNI	vs	CNI:	OR	1.22;	mTOR-I	with	CNI	
vs	CNI:	OR	0.86).	Graft	survival	was	negatively	affected	by	mTOR-I	monotherapy	(OR	
1.52)	but	not	when	combined	with	a	CNI	(OR	0.97).
Conclusion: Following	renal	transplantation	the	incidence	of	infections	is	lower	when	
mTOR-Is	are	combined	with	a	CNI	compared	to	a	standard	CNI	therapy.	Pneumonia	
occurs	more	often	under	mTOR-I	w/o	CNI.
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1  | INTRODUC TION
Side effect profile of a continuous immunosuppression following 
renal transplantation is well known.1
Cardiovascular	problems,	malignancy,	and	infections	are	the	main	
reasons for death with functioning graft and significant reasons for 
post-transplant	morbidity.	mTOR	inhibitors	raised	hopes	to	alleviate	
some of these problems. Infection post transplantation is a large 
field	and	thus	not	easy	to	assess.	Classifications	exist	which	divide	
infections	 in	operative	and	perioperative	nosocomial,	activation	of	
latent	infections,	and	community-acquired	infections.2	Furthermore,	
the vast number of different pathogens which can result in infec-
tions has to be taken into account. Viruses remain the most common 
cause of infection in transplanted patients.3,4	Recently,	mTOR-Is	ei-
ther	 in	 combination	with	 or	 instead	 of	CNI's	 have	 been	 shown	 to	
reduce	 the	 incidence	 of	 CMV	 infections	 significantly.5 The use of 
mTOR-Is	may	 also	 be	 beneficial	 against	 BK	 virus	 infections.6,7 On 
the	contrary,	affections	of	the	lung,	that	is,	pneumonitis	have	been	
known	to	be	increased	under	mTOR-Is.8
Do these effects translate into a net difference of the overall 
incidence	of	 infections	under	mTOR-Is	vs	CNIs?	Most	trials	do	not	
show a benefit for one regimen over the other.9,10	 Naturally,	 the	
large	prospective	randomized	trials	are	not	powered	to	detect	differ-
ences in the incidence of infections. This may contribute to the fact 
that description of infections and overall infection incidence remains 
imprecise all too often.
Here,	 we	 collected	 the	 existing	 evidence	 comparing	 mTOR-Is	
with	CNIs	as	basic	immunosuppressants	trying	to	draw	a	clearer	pic-
ture	on	their	effects	on	post-transplant	infections.
2  | MATERIAL S AND METHODS
2.1 | Identification of the eligible trials
Full	 reports	 of	 controlled	 prospective	 trials	 were	 searched	 via	
PubMed	(http://www.ncbi.nlm.nih.gov),	ScienceDirect	(http://www.
scien	cedir	ect.com),	and	the	Cochrane	Central	Register	of	Controlled	
Trials (http://www.mrw.inter scien ce.wiley.com/cochr ane/cochr ane_ 
clcen	tral_artic	les_fs.html)	 up	 to	 January	 2019	 using	 the	 optimally	
sensitive	strategies	for	the	identification	of	eligible	trials,	combined	
with	 the	 following	MeSH	 terms:	 (mTOR	 inhibitor	OR	sirolimus	OR	
everolimus)	AND	transplant	AND	infection.
2.2 | Inclusion criteria
Only	 prospective	 randomized	multicenter	 and	 three	 single	 center	
renal transplantation trials were included starting 2002. These trials 
were	 required	 to	 have	 at	 least	 two	 treatment	 arms,	 one	 with	 an	
mTOR-I	based	immunosuppression	either	with	or	without	a	CNI	and	
one	arm	containing	an	mTOR-I	free	CNI-based	immunosuppression.	
The	mTOR-I	had	to	be	introduced	within	3	months	after	the	trans-
plantation. The retrieved trials were screened for information on 
post-transplant	infections,	graft	and	patient	survival.	When	several	
publications	 showed	 the	 same	cohort	of	 patients,	 the	 information	
was	 summarized.	 Screening	 and	 inclusion	 of	 the	 articles	was	 per-
formed	by	two	reviewers	(S.W.,	J.A.).
2.3 | Data analysis
To	summarize	the	available	evidence,	we	calculated	odds	ratios	(ORs)	
for	 the	 incidence	 of	 post-transplant	 infections,	 patient	 and	 graft	
survival	 under	CNI-	 and	mTOR-I-based	 immunosuppression.	 Post-
transplant	infections	were	further	subdivided	in	“Overall	infections,”	
“pneumonia”	and	“urinary	tract	infections	(UTI)”	and	CMV.	If	no	in-
fection	was	observed	in	a	study	arm,	0.5	cases	were	added	to	both	
study arms to facilitate the calculation of the OR. If the incidence 
in	both	study	arms	was	zero,	the	incidence	was	set	to	1%	to	receive	
a OR of 1. Publication bias was assessed by plotting study results 
against	precision	of	 the	 study	 (funnel	plots)	 and	 the	according	 re-
gression tests.11	Between-study	heterogeneity	was	examined	using	
Q test for heterogeneity and the I2 statistic.12	Accounting	for	pos-
sible	heterogeneity	between	the	studies,	we	fitted	random	effects	
models to derive pooled estimators of the natural logarithms of the 
OR	using	 the	 restricted	maximum-likelihood	estimator.13 Standard 
errors were estimated using incidences and number of patients per 
group.	All	calculations	were	performed	using	the	meta and metafor 
package	in	the	statistical	software	package	R	(version	3.5.1).	P values 
below	.05	were	considered	significant,	and	all	confidence	limits	were	
on	the	95%	level.
2.4 | Data extraction and methodological quality
The	following	data	were	extracted	from	eligible	articles	by	two	re-
viewers	 (S.W.,	J.A.):	 type	of	transplanted	organ,	 induction	therapy,	
number	of	patients	per	treatment	arm,	mTOR-I	dose,	start	of	mTOR-I	
treatment	 post	 transplantation,	 biopsy-proven	 acute	 rejection	
(BPAR),	 patient	 and	graft	 survival,	 trough	 levels,	 follow-up	period,	
description,	 type	and	 incidence	of	events	of	post-transplant	 infec-
tions,	and	statistical	analysis	of	the	post-transplant	infections	under	
mTOR-Is	and	CNIs	both	alone	and	in	combination.
“Overall	 infections”	 included	 all	 documented	 infections	 up	 to	
12 months after transplantation. To get more specific information 
on	the	infections,	we	collected	data	on	viral,	bacterial,	fungal,	BKV,	
HSV,	CMV,	respiratory,	and	urogenital	infections.
K E Y W O R D S
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Methodological	 quality	 was	 assessed	 by	 three	 reviewers	
(S.W.,	 J.A.,	M.L.)	 using	 the	 Cochrane	 Collaboration's	 tool	 and	 ITT	
analysis.14,15
3  | RESULTS
3.1 | Included studies
The	 literature	 search	 produced	 954	 studies,	 of	which	 19	met	 the	
inclusion	criteria.	Thus,	a	 total	number	of	n	=	9861	patients	could	
be	included	(Figure	1).	The	trials	compared	mTOR-I	+	CNI	with	CNI	
treatment	(n	=	9)	(Table	S2)	and	mTOR-I	without	CNI	vs	CNI	(n	=	8)	
(Table	 S1).	 There	were	 two	 trials	 containing	 three	 different	 treat-
ment	arms,	mTOR-I,	mTOR-I	with	CNI,	and	CNI	(Table	S3).	Of	these	
19	trials,	11	RCTs	used	sirolimus	(SRL)	and	eight	everolimus	(ERL)	as	
the mTOR inhibitor. We only included studies with introduction of 
the	mTOR-I	within	3	months	after	the	transplantation.	Mostly,	 the	
mTOR-I	was	introduced	de	novo	or	very	early	(within	the	first	month;	
n	=	17,	89%).	The	majority	used	either	monoclonal	or	polyclonal	an-
tibodies	as	induction	therapy	(n	=	16,	84%).
All	of	 these	trials	delivered	data	on	the	 incidence	of	 infections	
as well as patient and graft survival 12 months post transplantation.
3.2 | Methodological quality
All	 of	 the	 19	 RCTs	 were	 considered	 to	 be	 of	 good	 methodologi-
cal	quality	according	to	the	Cochrane	Collaboration's	 tool	 (Figures	
S1-S3).
Almost	 all	 of	 the	RCTs	used	 intention	 to	 treat	 (ITT)	 to	analyze	
the	data	(90%).
F I G U R E  1  Flowchart	of	the	selection	
of articles
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-
Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097
For more information, visit www.prisma-statement.org.
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3.3 | Incidence of infections 12 months post 
transplantation
There was no significant difference for the incidence of overall in-
fections	under	mTOR-I	 (n	=	6,	SIR	=	4,	ERL	=	2)	 compared	 to	CNI	
treatment	(OR	0.97,	CI	0.82-1.14,	P	=	.68;	Figure	2).	The	funnel	plot	
did not reveal asymmetry (P	=	.50).	Also,	there	was	no	indication	of	
a significant heterogeneity between the trials (I2	=	0.00%,	Q test for 
heterogeneity: P	=	.76).
When	 the	 mTOR-I	 was	 combined	 with	 a	 CNI	 (n	 =	 9,	 SIR	 =	 4,	
ERL	=	5),	there	was	a	significantly	reduced	odds	ratio	for	overall	in-
fections	compared	to	CNI	treatment	(OR	0.76,	CI	0.68-0.85,	P	<	.001,	
Figure	3).	There	was	no	indication	of	publication	bias	in	the	funnel	
plot as indicated by the regression test showing no significance for 
the asymmetry (P	=	.87).	There	was	also	no	significant	heterogeneity	
between the studies (I2	=	0.00%,	Q test for heterogeneity: P	=	.86).
3.4 | Incidence of pneumonia 12 months post 
transplantation
There	were	seven	RCTs	(SIR	=	5,	ERL	=	2)	describing	the	incidence	
of pneumonia. The odds ratio for pneumonia was significantly 
increased	under	an	mTOR-I	 therapy	without	a	CNI	 compared	 to	a	
CNI	treatment	(OR	2.09,	CI	1.41-3.12,	P	<	.001;	Figure	4A).	When	the	
mTOR-I	was	combined	with	a	CNI	(n	=	3,	SIR	=	2,	ERL	=	1),	there	was	
no	significant	difference	compared	to	the	CNI	treatment	alone	(OR	
1.42,	CI	0.60-3.35,	P	=	.42;	Figure	4B).
There was no indication of publication bias in the funnel plot 
as indicated by the regression test showing no significance for 
the	 asymmetry	 in	 the	 analyses	 for	 the	 combination	 vs	 CNI	 ther-
apy (P	=	.77).	A	significant	asymmetry	was	seen	for	the	analysis	of	
mTOR-I	 vs	CNI	 (P	 =	 .018).	 There	was	no	 significant	heterogeneity	
between	the	studies	in	both	analyses	(mTOR-I	vs	CNI:	I2	=	0.00%,	Q 
test for heterogeneity: P	=	.54,	mTOR-I	+	CNI	vs	CNI:	I2	=	0.00%,	Q 
test for heterogeneity: P	=	1.00).
3.5 | Incidence of urinary tract infections (UTI) 
12 months post transplantation
Six	RCTs	(SIR	=	4,	ERL	=	2)	with	mTOR-I	vs	CNI	treatment	showed	data	
on	UTIs.	There	was	no	difference	for	the	incidence	of	UTIs	between	
the	 treatment	 groups	 (OR	 0.86,	 CI	 0.71-1.05,	 P	 =	 .14;	 Figure	 5A).	
Comparable	results	were	seen	when	the	mTOR-I	was	combined	with	
a	CNI	(n	=	4,	SIR	=	2,	ERL	=	2,	OR	0.89,	CI	0.71-1.12,	P	=	.33;	Figure	5B).
F I G U R E  2  Forest	plot	indicating	the	
odds ratios of the occurrence of infections 
on	mTOR-I	vs	CNI	treatment	post	
transplantation
F I G U R E  3  Forest	plot	indicating	the	
odds ratios of the occurrence of infections 
on	mTOR-I	+	CNI	vs	CNI	treatment	post	
transplantation
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F I G U R E  4   Incidence of pneumonia 
post	transplantation.	A,	Forest	plot	
indicating the odds ratios of the 
occurrence	of	pneumonia	on	mTOR-I	
vs	CNI	treatment	post	transplantation.	
B,	Forest	plot	indicating	the	odds	ratios	
of the occurrence of pneumonia on 
mTOR-I	+	CNI	vs	CNI	treatment	post	
transplantation
F I G U R E  5   Incidence of urinary tract 
infections	post	transplantation.	A,	Forest	
plot indicating the odds ratios of the 
occurrence of urinary tract infections 
on	mTOR-I	vs	CNI	treatment	post	
transplantation.	B,	Forest	plot	indicating	
the odds ratios of the occurrence of 
urinary	tract	infections	on	mTOR-I	+	CNI	
vs	CNI	treatment	post	transplantation
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There was no indication of publication bias in the funnel plot 
as indicated by the regression test showing no significance for 
the	 asymmetry	 (mTOR-I	 vs	CNI:	P	 =	 .46,	mTOR-I	 +	CNI	 vs	CNI:	
P	=	.21).	There	was	also	no	significant	heterogeneity	between	the	
studies	 (mTOR-I	 vs	 CNI:	 I2	 =	 32.20%,	Q test for heterogeneity: 
P	=	.19;	mTOR-I	+	CNI	vs	CNI:	I2	=	0.00%,	Q test for heterogeneity: 
P	=	.49).
3.6 | Incidence of CMV infections 12 months post 
transplantation
Four	RCTs	(SIR	=	2,	ERL	=	2)	on	mTOR–I	w/o	CNI	vs	CNI	were	in-
cluded.	 The	 meta-analysis	 showed	 a	 significant	 benefit	 for	 the	
mTOR-I	(OR	0.46,	CI	0.32-0.66,	P	<	.001;	Figure	6A).	This	beneficial	
anti-CMV	effect	was	also	present	under	the	combination	of	mTOR-
I	+	CNI	 (n	=	9,	SIR	=	4,	ERL	=	5,	OR	0.30,	CI	0.17-0.51,	P < .001; 
Figure	6B).
There was no indication of publication bias in the funnel plot 
as indicated by the regression test showing no significance for the 
asymmetry	(mTOR-I	vs	CNI:	P	=	.66,	mTOR-I	+	CNI	vs	CNI:	P	=	.47).	
There	was	also	no	significant	heterogeneity	between	mTOR-I	vs	CNI	
studies (I2	=	2.7%,	Q test for heterogeneity: P	=	.38).	The	heteroge-
neity	was	significant	for	mTOR-I	+	CNI	vs	CNI	therapy	(I2	=	63.6%,	Q 
test for heterogeneity: P	=	.005).
3.7 | Graft survival (censored for death) 12 months 
post transplantation
There	were	 seven	RCTs	 included	 in	 this	 analysis	 comparing	mTOR-I	
with	CNI	treatment.	SIR	was	the	mTOR-I	used	in	four	RCTs	and	ERL	in	
three RCTs. The ensuing analysis implied a higher risk for graft loss and 
therefore	a	negative	effect	for	graft	survival	under	mTOR-I	therapy	(OR	
1.52,	CI	1.05-2.19,	P	=	.026;	Figure	7A).	The	regression	test	for	funnel	
plot asymmetry was not significant (P	=	.80).	There	was	no	heterogene-
ity between the RCTs (I2	=	0.00%,	Q test for heterogeneity: P	=	.71).
Eight	RCTs	 (SIR	=	1,	ERL	=	7)	 showed	 results	on	graft	 survival	
comparing	mTOR-I	with	CNI	and	CNI.	There	was	no	significant	dif-
ference for graft loss and survival between treatment groups (OR 
0.97,	CI	0.66-1.43,	P	=	.88;	Figure	7B).
The regression test for funnel plot asymmetry was not sig-
nificant (P	 =	 .46).	 There	was	 no	 heterogeneity	 between	 the	 RCTs	
(I2	=	12.36%,	Q test for heterogeneity: P	=	.48).
F I G U R E  6   Incidence	of	CMV	
infections	post	transplantation.	A,	Forest	
plot indicating the odds ratios of the 
occurrence	of	CMV	infections	on	mTOR-I	
vs	CNI	treatment	post	transplantation.	
B,	Forest	plot	indicating	the	odds	ratios	
of	the	occurrence	of	CMV	infections	on	
mTOR-I	+	CNI	vs	CNI	treatment	post	
transplantation
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3.8 | Patient survival 12 months post 
transplantation
There	were	10	RCTs	included	in	this	analysis	comparing	mTOR-I	with	
CNI	treatment.	SIR	was	the	mTOR-I	used	in	seven	RCTs	and	ERL	in	
three RCTs. There was no significant difference for patient survival 
between	mTOR-I	 and	CNI	 therapy	 (OR	 1.22,	 CI	 0.77-1.95,	P	 =	 .4;	
Figure	8A).
The regression test for funnel plot asymmetry was not significant 
(P	=	.92).	There	was	no	heterogeneity	between	the	RCTs	(I2	=	0.00%,	
Q test for heterogeneity: P	=	.93).
There was also no difference for the patient survival between 
treatment	groups	if	the	mTOR-I	was	combined	with	a	CNI	(n	=	12,	
SIR	=	4,	ERL	=	8,	OR	0.86,	CI	0.59-1.27,	P	=	.45;	Figure	8B).
The regression test for funnel plot asymmetry was not significant 
(P	=	.70).	There	was	no	heterogeneity	between	the	RCTs	(I2	=	8.04%,	
Q test for heterogeneity: P	=	.72).
4  | DISCUSSION
This	is	a	systematic	review	analyzing	the	impact	of	mTOR-Is	vs	CNIs	
on	 infections	 following	 renal	 transplantation.	 Analyses	 were	 per-
formed	on	“overall	infections”	and	infection	subtypes	as	urogenital,	
respiratory	and	CMV	infections.	Data	of	19	RCTs	with	n	=	9861	pa-
tients	were	included,	making	this	analysis	to	the	largest	of	its	kind	on	
this	 topic.	 Infections	occur	most	often	 in	 the	early	post-transplant	
period when multiple immunosuppressive drugs at high concentra-
tions	 are	 administered.	 Therefore,	 only	 those	RCTs	were	 included	
which	had	the	mTOR-I	introduced	de	novo	or	up	to	3	months.
Infections are responsible for morbidity and mortality in the im-
munosuppressed patients following renal transplantation.16	 Most	
common are operative and perioperative nosocomial bacterial and 
fungal	infections,	the	reactivation	of	latent	infections,	and	also	inva-
sive	fungal	as	well	as	donor-derived	infections.17
In	the	early	phase	<1	month	after	transplantation,	infections	are	
mostly related to surgical complications.2 It is widely accepted that 
mTOR-Is	are	associated	with	surgical	wound	complications	and	pro-
longed wound healing after surgery.18-20 This may have contributed 
to	our	data.	The	 trials	had	 introduced	 the	mTOR-I	within	 the	 first	
3	months	after	transplantation.	More	specifically,	six	of	the	included	
trials	(75%)	on	mTOR-I	without	an	additional	CNI	vs	CNI	started	the	
mTOR-I	de	novo,	89%	within	the	first	month	after	the	transplanta-
tion.	Unfortunately,	the	trials	most	often	did	not	distinguish	between	
non-infectious	wound	complications	 (wound	dehiscence,	 incisional	
hernia,	etc)	and	actual	wound	infections.	Neither	was	there	enough	
information	to	draw	a	subtle	conclusion	between	wound	and	“other”	
infections.
We found that there is no significant difference for the incidence 
of	overall	infections	for	an	mTOR-I	monotherapy	in	comparison	with	
standard	CNI	regimen	within	12	months	post	transplantation.	Our	
data	compare	well	with	a	 longitudinal	cohort	study	 from	Australia	
and	New	Zealand	with	9353	patients	that	showed	no	significant	dif-
ference	for	de	novo	mTOR-I	vs	CNI	treatment	regarding	infections	
F I G U R E  7   Graft survival censored for 
death	post	transplantation.	A,	Forest	plot	
indicating the graft survival censored for 
death	on	mTOR-I	vs	CNI	treatment.	B,	
Forest	plot	indicating	the	graft	survival	
censored	for	death	on	mTOR-I	+	CNI	vs	
CNI
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causing	death	(13%	vs	16%),9 and another report where the overall 
infection	 rate	was	not	 significantly	 different	 under	 SRL	 (sirolimus)	
compared	to	CsA	(17.4%	vs	21.8%).10
Unexpectedly,	 our	 data	 indicated	 that	 infections	 occur	 signifi-
cantly	less	often	when	the	mTOR-I	is	combined	with	a	CNI	compared	
to	a	regular	CNI	therapy.	This	was	surprising,	since	the	combination	
of these two substance classes was thought to have rather an addi-
tive immunosuppressive effect.
The	incidence	of	CMV	infections	was	significantly	reduced	in	
accordance to previously published reports.5,21-23 This may also 
hold true for BK virus infections.24,25 BK viremia in patients who 
were changed from tacrolimus to sirolimus after detection of 
BKVAN	decreased	by	more	than	50%	in	the	first	2	months	after	
mTOR-I	initiation	and	was	almost	undetectable	at	19	months	after	
the conversion.25	A	meta-analysis	primarily	on	CMV	and	BKV	in-
fections	comparing	mTOR-Is	with	CNIs	described	an	8%	increase	
of	 overall	 infections	 (viral,	 bacterial,	 and	 fungal)	 under	 mTOR-I	
monotherapy	(OR	1.08,	CI	1.02-1.15)	but	no	difference	when	the	
mTOR-I	was	 combined	with	 a	CNI.	CMV	 infections	were	 signifi-
cantly	 reduced	 under	mTOR-Is	 in	 comparison	with	 CNI	 therapy,	
whereas no such effect was seen for BKV infections. Trial com-
position was substantially different to our analysis. There was no 
information	presented	on	the	time	of	mTOR-I	initiation.	Follow-up	
ranged	from	6	months	to	5	years,	and	studies	were	not	confined	to	
kidney transplantation.26
The	following	scenarios	may	serve	as	potential	explanations	for	
our	findings:	Using	the	combination,	mTOR-I	and	CNI	trough	levels	
are	 substantially	 reduced.	Nonetheless,	 the	 beneficial	 antiviral	 ef-
fect is still present as we and others could show.5	Maybe,	the	pos-
itive	antiviral	 effect	of	 the	mTOR-Is	even	under	 the	 reduced	dose	
simply outweighs the additional immunosuppression of the combi-
nation therapy.27,28	Another	explanation	may	be	 that	mTOR-Is	 are	
known not only to suppress but also enhance certain immune reac-
tions	as	memory	T-cell	functions,23	quantity	and	quality	of	virus-spe-
cific	CD8	T	 cells	 and	memory	precursor	 cells.23	 Furthermore,	 SRL	
was	shown	to	enhance	 the	effector	 to	memory	T-cell	 transition.23 
Another	 immune-stimulatory	 effect	 caused	 by	 the	 inhibition	 of	
mTOR	is	an	increase	of	proinflammatory	cytokines	such	as	IL-12	and	
IL-1beta,	while	the	anti-inflammatory	cytokine	IL-10	is	suppressed.29 
In	addition,	 increased	MHC	antigen	presentation	via	autophagy	 in	
monocytes/macrophages and dendritic cells and counteracting im-
munosuppressive effects of steroids have been reported.29,30
Which of these effects is responsible for the lower incidence of 
infections under the combination therapy remains speculative and 
cannot be answered by this analysis.
The	manuscripts	were	 also	 screened	 for	 bacterial,	 fungal,	 and	
community-acquired	 infections.	 Unfortunately,	 to	 these	 data	 pre-
sentation had been incomplete. Pneumonia and urinary tract infec-
tions	were	the	only	“other”	more	specific	sites	of	infection	rendering	
enough data for statistically sound analyses.
F I G U R E  8   Patient survival post 
transplantation.	A,	Forest	plot	indicating	
the	patient	survival	on	mTOR-I	vs	CNI	
treatment.	B,	Forest	plot	indicating	the	
patient	survival	on	mTOR-I	+	CNI	vs	CNI
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Pneumonia is an important risk factor for morbidity and mortal-
ity	in	transplanted	patients.	A	retrospective	analysis	on	406	kidney	
transplant	recipients	showed	that	20%	of	the	transplanted	patients	
suffered	 from	pneumonia,	which	were	mostly	 caused	by	bacterial	
infections.31
We found a significantly increased risk for pneumonia in trans-
planted	patients	 treated	with	an	mTOR-I	 compared	 to	a	CNI.	This	
effect	was	alleviated	and	no	longer	significant	when	mTOR-Is	were	
combined	with	CNIs.
Non-infectious	pneumonitis,	which	can	be	mistaken	for	infec-
tious	pneumonitis,	may	be	a	potential	explanation	for	these	data.	
Non-infectious	pneumonitis	is	rare.	There	exists	a	dose-response	
relationship—especially	 under	 high	 concentrations,	 which	 are	
preferably	used	 in	 the	oncological	 field,	 in	which	pneumonitis	 is	
a	well-recognized	 problem.	 It	 is	 observed	 in	 about	 a	 third	 of	 all	
cancer	 patients,	 although	 only	 around	 10%	will	 have	 symptoms	
necessitating treatment.32	 Therefore,	 it	 is	 more	 likely	 to	 occur	
under	a	mTOR-I	therapy	without	a	CNI,	when	the	mTOR-concen-
tration used is higher than in combination therapy. On pulmonary 
CT	scan,	non-infectious	pneumonitis	commonly	presents	with	an	
organizing	pneumonia-like	pattern,	a	nonspecific	interstitial	pneu-
monitis-like	 pattern,	 or	 both.33	 A	 recent	 randomized	 controlled	
trial,	 the	 “3C	 study,”	 came	 to	 similar	 results,	with	 raised	 pulmo-
nary	infections	under	SIR	based	therapy,	which	were	explained	by	
possible misclassification (attribution of symptoms to an infective 
cause	rather	than	to	a	direct	drug	effect).34
Urogenital	infections	(UTI)	are	also	a	major	problem	and	repre-
sent	with	more	than	30%	the	most	common	infection	after	kidney	
transplantation.	Etiology	 is	mostly	attributed	 to	Escherichia	coli	 in	
more	than	35%,	Enterobacter	sp	in	about	20%,	Klebsiella	pneumo-
niae	in	11%,	and	to	Pseudomonas	aeruginosa	in	6%.35
In	our	 analyses,	 there	was	no	difference	 for	 the	 incidence	of	
UTI	 neither	 for	mTOR-I	monotherapy	 nor	 the	 combination	 ther-
apy	with	CNI	vs	a	standard	CNI	treatment.	This	is	in	line	with	an-
other	meta-analysis	which	 showed	 similar	 results	with	 an	OR	 of	
1.00	for	urogenital	 infections	comparing	mTOR-I	+	CNI	with	CNI	
treatment.36
We	included	trials	using	ATG	as	well	as	Daclizumab/Basiliximab	
induction.	There	exists	 evidence	 from	>15	years	 ago	 that	ATG	 in-
duction	may	cause	more	infections	than	IL-2R	antibodies	following	
renal transplantation.37	Advances	in	the	immunosuppressive	proto-
cols	as	well	as	anti-infectious	therapy/prophylaxis	most	 likely	have	
contributed to the data of more recent trials which could not confirm 
a	significant	difference	between	poly-	and	monoclonal	antibodies	as	
induction therapy.38,39
As	 a	 secondary	 outcome	 of	 this	 study,	 we	 also	 analyzed	 pa-
tient and graft survival. Graft survival censored for death was not 
different	 under	 the	 combination	 of	mTOR-I	 and	CNI	 compared	 to	
a	CNI	therapy.	When	the	mTOR-I	was	administered	without	a	CNI,	
however,	graft	survival	was	significantly	worse	compared	to	a	CNI	
therapy. It has been repetitively shown that a de novo or an early 
“monotherapy”	 with	 an	 mTOR-I	 results	 in	 a	 higher	 percentage	 of	
BPARs	and	a	high	number	of	therapy	dropouts.40-43
We did not find a significant difference concerning patient 
survival	between	the	groups	regardless	of	whether	mTOR-Is	were	
administered	with	or	without	a	CNI.	This	confirms	the	findings	of	a	
previous	large	meta-analysis	and	the	most	recent	prospective	ran-
domized	 trials	 (ZEUS,	 TRANSFORM,	 HERAKLES).44-47	 However,	
data have also been published which show a worse survival under 
mTOR-Is.	 Especially,	 registry	 data	 from	 ANZDATA9 and SRTR48 
showed an inferior outcome. Registry data seem not suitable for 
this comparison since many transplant patients are changed onto 
an	mTOR-I	whenever	malignancy	or	deteriorating	transplant	func-
tion occurs—both situations for which an earlier death would be 
expected.	Furthermore,	many	patients	had	been	 included	 in	ear-
lier	years	when	higher	doses	of	mTOR-Is	were	standard.	The	only	
trial	 to	 date	 that	 used	 randomized	 controlled	 data	 and	 showed	
a	worse	 survival	 under	mTOR-Is	was	 the	meta-analysis	 by	Knoll	
et al.49 Trial composition had been substantially different using 
many trials from a very early era (five of 21 trials were published 
before	 2002)	 when	 the	 experience	 with	 the	 mTOR-Is	 was	 low	
and	extraordinary	high	loading	and	maintenance	doses	of	SRL	de	
novo	were	used	(76%	of	the	selected	RCTs).	Importantly,	mortality	
under	 “low-dose”	 SRL,	 as	 is	 preferably	 used	 nowadays	 in	 trans-
plantation,	was	not	increased.
Our	study	has	some	limitations.	Naturally,	the	primary	endpoint	
in	 the	 included	RCTs	was	on	survival	and	BPAR	and	not	 infection.	
Also,	there	was	not	a	general	definition	for	infection	and	most	of	the	
trials did not record or show detailed information on the infections 
that	occurred.	This	made	more	 specific	 analyses	 impossible.	Most	
studies	did	not	allow	calculating	hazard	ratios,	which	would	be	the	
primary	choice	for	this	type	of	data.	However,	given	the	relatively	
short	observation	time	of	12	months,	we	do	not	expect	to	have	in-
troduced a large bias.
Following	 renal	 transplantation,	 the	 overall	 incidence	 of	 infec-
tions	 is	not	 increased	under	mTOR-Is	vs	CNIs.	The	combination	of	
mTOR-I	with	CNI	even	reduces	the	incidence	of	infections.	This	may	
primarily	be	explained	by	the	powerful	anti-CMV	effect	of	mTOR-Is	
as	 we	 could	 not	 find	 beneficial	 effects	 of	 mTOR-Is	 over	 CNIs	 on	
other infections.
Lung	 affections	 may	 be	 more	 often	 under	 mTOR-Is	 with-
out	CNIs.	 This	 could	 be	 related	 to	 the	 difficulty	 to	 differentiate	
between	 infectious	 and	 non-infectious	 pneumonitis.	 Incidence	
of	 urogenital	 infections	 under	mTOR-Is	 vs	CNIs	 is	 not	 different.	
Mortality	is	not	increased	with	an	mTOR-I	therapy,	and	best	pro-
tection against graft loss is provided by a combination therapy of 
an	mTOR-I	and	a	CNI.
Future	randomized	trials	should	deliver	more	detailed	 informa-
tion	on	post-transplant	infections	to	allow	for	more	subtle	analyses.
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